Last reviewed · How we verify

Aliskiren + Valsartan — Competitive Intelligence Brief

Aliskiren + Valsartan (Aliskiren + Valsartan) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct renin inhibitor + angiotensin II receptor blocker combination. Area: Cardiovascular.

marketed Direct renin inhibitor + angiotensin II receptor blocker combination Renin and AT1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Aliskiren + Valsartan (Aliskiren + Valsartan) — HeartDrug Research LLC. Aliskiren and valsartan work together to lower blood pressure by blocking the renin-angiotensin-aldosterone system at two different points: aliskiren directly inhibits renin, while valsartan blocks angiotensin II receptors.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aliskiren + Valsartan TARGET Aliskiren + Valsartan HeartDrug Research LLC marketed Direct renin inhibitor + angiotensin II receptor blocker combination Renin and AT1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct renin inhibitor + angiotensin II receptor blocker combination class)

  1. HeartDrug Research LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aliskiren + Valsartan — Competitive Intelligence Brief. https://druglandscape.com/ci/aliskiren-valsartan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: